NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Forecast, Price & News

$0.88

+0.04 (+4.76%)

(As of 05/26/2023 ET)

Compare

Today's Range: $0.82
▼
$0.94
50-Day Range: $0.48
▼
$0.88
52-Week Range: $0.47
▼
$2.52

Volume: 342,023 shs
Average Volume: 162,004 shs
Market Capitalization: $14.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Context Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 354.5% Upside
$4.00 Price Target
Short Interest: Healthy
0.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.26) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

470th out of 1,018 stocks

Pharmaceutical Preparations Industry

216th out of 498 stocks

3.0

Analyst's Opinion

Consensus Rating
Context Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Context Therapeutics has a forecasted upside of 354.5% from its current price of $0.88.
Amount of Analyst Coverage
Context Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.68% of the float of Context Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Context Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Context Therapeutics has recently decreased by 15.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Context Therapeutics does not currently pay a dividend.
Dividend Growth
Context Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CNTX.

3.0

News and Social Media Coverage

News Sentiment
Context Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for CNTX on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Context Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.66% of the stock of Context Therapeutics is held by insiders.
Percentage Held by Institutions
Only 25.88% of the stock of Context Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Context Therapeutics are expected to grow in the coming year, from ($1.26) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Context Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Context Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Context Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Context Therapeutics (NASDAQ:CNTX) Stock

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

May 20, 2023 | americanbankingnews.com

Analysts Offer Predictions for Context Therapeutics Inc.'s Q2 2023 Earnings (NASDAQ:CNTX)

May 17, 2023 | americanbankingnews.com

Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Increase in Short Interest

May 27, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>

May 16, 2023 | benzinga.com

ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine

May 16, 2023 | americanbankingnews.com

Context Therapeutics Inc. (NASDAQ:CNTX) to Post Q2 2023 Earnings of ($0.23) Per Share, HC Wainwright Forecasts

May 11, 2023 | finanznachrichten.de

Context Therapeutics Inc.: Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 11, 2023 | markets.businessinsider.com

Context Therapeutics (CNTX) Gets a Hold from H.C. Wainwright

May 10, 2023 | finance.yahoo.com

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 27, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

April 28, 2023 | americanbankingnews.com

Reviewing Context Therapeutics (CNTX) & The Competition

April 24, 2023 | proactiveinvestors.com

Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting

April 18, 2023 | finance.yahoo.com

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

April 18, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)

April 14, 2023 | proactiveinvestors.com

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar

April 14, 2023 | benzinga.com

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference

April 3, 2023 | finance.yahoo.com

Context Therapeutics to Participate in Two April 2023 Investor Conferences

March 29, 2023 | americanbankingnews.com

Context Therapeutics Inc. to Post Q1 2023 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:CNTX)

March 25, 2023 | americanbankingnews.com

HC Wainwright Downgrades Context Therapeutics (NASDAQ:CNTX) to Neutral

March 24, 2023 | bizjournals.com

Context Therapeutics discontinues development of lead drug candidate, shifts to new target

March 24, 2023 | americanbankingnews.com

FY2027 Earnings Estimate for Context Therapeutics Inc. (NASDAQ:CNTX) Issued By HC Wainwright

March 23, 2023 | proactiveinvestors.com

Context Therapeutics announces pipeline update with FY 2022 financial results

March 23, 2023 | finanznachrichten.de

Context Therapeutics Inc.: Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

March 23, 2023 | markets.businessinsider.com

H.C. Wainwright downgrades Context Therapeutics (CNTX) to a Hold

March 22, 2023 | finance.yahoo.com

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

March 15, 2023 | proactiveinvestors.com

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

March 15, 2023 | finance.yahoo.com

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

February 13, 2023 | benzinga.com

Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Company Calendar

Today: 5/27/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CNTX
CUSIP: N/A
CIK: 1842952
Web: www.contexttherapeutics.com
Phone: 267-225-7416
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +354.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.45%
Return on Assets: -45.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.86
Quick Ratio: 9.86

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 0.49

Miscellaneous

Outstanding Shares: 15,970,000
Free Float: 14,903,000
Market Cap: $14.05 million
Optionable: Not Optionable
Beta: 2.27

Key Executives

Mr. Martin A. Lehr (Age 38)
Co-Founder, Pres, CEO & Director
Comp: $523.71k

Ms. Jennifer Minai-Azary (Age 44)
CFO & Treasurer
Comp: $404.33k

Mr. Alex C. Levit Esq. (Age 43)
Chief Legal Officer & Corp. Sec.
Comp: $490.82k

Dr. Felix Kim Ph.D.
Co-founder & Chair of Scientific Advisory Board

Mr. Christopher Beck M.B.A.
Sr. VP of Operations

Dr. Tarek Sahmoud M.D. (Age 61)
Ph.D., Chief Medical Officer

Dr. Evan G. Dick (Age 70)
Sr. VP of R&D

Ms. Elizabeth Nemchik CPA
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNTX Stock - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNTX, but not buy additional shares or sell existing shares.
View CNTX analyst ratings or view top-rated stocks.
What is Context Therapeutics' stock price forecast for 2023?: 1 equities research analysts have issued 1-year price objectives for Context Therapeutics' stock. Their CNTX share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price.
View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts.
How have CNTX shares performed in 2023?: Context Therapeutics' stock was trading at $0.6517 at the beginning of the year. Since then, CNTX shares have increased by 35.0% and is now trading at $0.88.
View the best growth stocks for 2023 here.
Are investors shorting Context Therapeutics?: Context Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 100,000 shares, a decrease of 15.6% from the April 30th total of 118,500 shares. Based on an average trading volume of 96,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.7% of the company's shares are sold short.
View Context Therapeutics' Short Interest.
When is Context Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CNTX earnings forecast.
When did Context Therapeutics IPO?: (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

What is Context Therapeutics' stock symbol?: Context Therapeutics trades on the NASDAQ under the ticker symbol "CNTX."
Who are Context Therapeutics' major shareholders?: Context Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Investments LP (0.35%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr.
View institutional ownership trends.
How do I buy shares of Context Therapeutics?: Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Context Therapeutics' stock price today?: One share of CNTX stock can currently be purchased for approximately $0.88.
How much money does Context Therapeutics make?: Context Therapeutics (NASDAQ:CNTX) has a market capitalization of $14.05 million. The company earns $-14,840,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.
How can I contact Context Therapeutics?: Context Therapeutics' mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The official website for the company is www.contexttherapeutics.com. The company can be reached via phone at 267-225-7416.

This page (NASDAQ:CNTX) was last updated on 5/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial